Tumor anemia and thrombocytosis in patients with vulvar cancer

Hefler, L, Mayerhofer, K, Leibman, B, Obermair, A, Reinthaller, A, Kainz, C and Tempfer, C (2000) Tumor anemia and thrombocytosis in patients with vulvar cancer. Tumor Biology, 21 5: 309-314. doi:10.1159/000030136


Author Hefler, L
Mayerhofer, K
Leibman, B
Obermair, A
Reinthaller, A
Kainz, C
Tempfer, C
Title Tumor anemia and thrombocytosis in patients with vulvar cancer
Journal name Tumor Biology   Check publisher's open access policy
ISSN 1010-4283
Publication date 2000-09-01
Year available 2000
Sub-type Article (original research)
DOI 10.1159/000030136
Open Access Status DOI
Volume 21
Issue 5
Start page 309
End page 314
Total pages 6
Place of publication BASEL
Publisher KARGER
Language eng
Abstract The aim of our study was to determine the prevalence of tumor anemia and thrombocytosis in patients with vulvar cancer, and to evaluate the prognostic value or pretreatment hemoglobin (Hb) and platelet count regarding disease-free and overall survival of patients with vulvar cancer. We measured pretreatment Hb and platelet count in 62 patients with squamous cell vulvar cancer. The results were correlated to clinical data. Median Hb and platelet count in patients with vulvar cancer were 13.1 g/dl (range 8.3-16.2) and 268,500/mu l (range 88,000-778,000), respectively. Cut-off levels of 12 g/dl and 300,000/mu l were selected for tumor anemia and tumor thrombocytosis, respectively according to published criteria. Tumor anemia and tumor thrombocytosis were present in 30.6 and 27.4% of patients with vulvar cancer, respectively. In a univariate analysis tumor stage and tumor thrombocytosis were significantly associated with a shortened disease-free (log-rank test, p < 0.001 and p = 0.003, respectively) and overall survival (log-rank test, p < 0.001 and p < 0.001, respectively). Tumor anemia was not associated with a shortened disease-free, but with a shortened overall survival of patients with vulvar cancer (log-rank test, p = 0.1 and p = 0.002, respectively). A multivariate Cox regression model considering tumor stage, tumor anemia, and tumor thrombocytosis showed, however, that pretreatment Hb and platelet count did not confer additional prognostic information to that already obtained by the established prognosticator tumor stage on disease free (multivariate Cox regression model, p = 0.8, p = 0.2, and p = 0.003, respectively) and overall survival (multivariate Cox regression model, p = 0.4, p = 0.5, and p = 0.04, respectively). Pretreatment tumor anemia and tumor thrombocytosis were associated with a poor prognosis, but were not an independent predictor of outcome in patients with vulvar cancer. Copyright (C) 2000 S. Karger AG, Basel.
Keyword anemia
thrombocytosis
vulvar cancer
prognosis
Prognostic Factors
Cervical-Cancer
Carcinoma
Survival
Women
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Unknown

Document type: Journal Article
Sub-type: Article (original research)
Collection: ResearcherID Downloads - Archived
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 43 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 48 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Sun, 11 Sep 2011, 00:31:12 EST by System User